Company Overview - Merck & Co. is based in Kenilworth, NJ, and has over six blockbuster products, with Keytruda being a PD-L1 inhibitor approved for various cancers, accounting for approximately 50% of its pharmaceutical sales [11] - Keytruda has significantly contributed to Merck's steady revenue growth in recent years, although there are concerns regarding the company's heavy reliance on this drug and the need for product diversification [11] Investment Ratings - Merck is currently rated as 3 (Hold) on the Zacks Rank, with a VGM Score of B [12] - The stock has a Momentum Style Score of A, and its shares have increased by 3.8% over the past four weeks [12] Earnings Estimates - For fiscal 2025, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising to $8.94 per share [12] - Merck has an average earnings surprise of +3.9%, indicating a positive trend in earnings performance [12] Investment Considerations - With a solid Zacks Rank and high Momentum and VGM Style Scores, Merck is recommended for investors' consideration [13]

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Insights - Merck holds a strong position in the oncology market, primarily driven by its PD-L1 inhibitor, Keytruda, which accounted for over 50% of the company's pharmaceutical sales in the first half of 2025 [1][9] - Keytruda's sales increased approximately 7% in the first half of 2025, and the company anticipates continued growth, particularly in early lung cancer indications [2][3] Sales Performance - The Zacks Consensus Estimate for Keytruda's sales in Q3 2025 is $8.50 billion, with an internal estimate of $8.51 billion [3] - Keytruda is expected to continue being the primary revenue driver in the second half of 2025, supported by the Animal Health segment and new product launches [3] Regulatory Developments - The FDA approved a subcutaneous formulation of Keytruda, known as Keytruda Qlex, which enhances patient convenience and extends patent protection beyond 2028 [4][9] Competitive Landscape - Keytruda faces competition from other PD-L1 inhibitors such as Bristol-Myers' Opdivo, Roche's Tecentriq, and AstraZeneca's Imfinzi, which have also shown strong sales growth [6][7] - Opdivo generated $4.82 billion in sales in the first half of 2025, up 9% year-over-year, while Tecentriq and Imfinzi reported CHF 1.7 billion and $2.72 billion in sales, respectively [6][7] Financial Performance - Year-to-date, Merck's shares have declined by 12.1%, underperforming the industry, sector, and S&P 500 [8] - Merck's shares trade at a price/earnings ratio of 9.15, which is lower than the industry average of 15.88 and its 5-year mean of 12.66, indicating attractive valuation [10] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share has slightly increased from $8.92 to $8.93, while the estimate for 2026 has decreased from $9.61 to $9.58 over the past 60 days [11]

Core Viewpoint - Merck (MRK) stock is highlighted for its monopoly-like high margins available at a discounted price, making it an attractive investment opportunity [1] Financial Performance - Revenue growth for Merck is reported at 1.8% for the last twelve months (LTM) and an average of 3.7% over the last three years [8] - Recent profitability metrics include approximately 29.1% operating cash flow margin and 31.2% operating margin for LTM [8] - Long-term profitability averages show about 27.2% operating cash flow margin and 22.6% operating margin over the last three years [8] - The stock is currently offered at a price-to-sales (P/S) multiple of 3.5, representing a 22% discount compared to one year ago [8] Investment Strategy - The Trefis High Quality Portfolio, which includes Merck, has a record of outperforming benchmark indices, including the S&P 500, S&P mid-cap, and Russell 2000 [11] - The selection process for stocks focuses on those with market capitalizations over $10 billion, high cash flow from operations margins, and those that have significantly decreased in value over the past year [6] Market Dynamics - The average 12-month forward returns for selected stocks are close to 19%, with a win rate of around 72% for positive returns [9]

Core Insights - Merck is set to present new research at the ESMO Congress 2025, showcasing over 100 abstracts across more than 20 cancer types, highlighting its commitment to advancing cancer treatment outcomes [1][2]. Group 1: Existing Medicines - Key data on existing medicines in Merck's portfolio will be presented, including findings for KEYTRUDA, LENVIMA, WELIREG, and KEYTRUDA QLEX [2][3]. - Research on KEYTRUDA's impact in bladder, ovarian, and lung cancers will be featured in three Presidential Symposium presentations [2]. Group 2: Investigational Candidates - New data for investigational antibody-drug conjugates (ADCs) will be presented, including raludotatug deruxtecan and ifinatamab deruxtecan, both discovered by Daiichi Sankyo [4]. - Research on sacituzumab tirumotecan, a TROP2-directed ADC, will be shared in four presentations focusing on lung, breast, cervical, and prostate cancers [4]. Group 3: Key Studies - First-time data from the Phase 3 KEYNOTE-905/EV-303 study evaluating KEYTRUDA plus Padcev for muscle-invasive bladder cancer will be presented [6]. - Five-year exploratory follow-up data from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA for advanced endometrial cancer will be showcased [6]. - Ten-year follow-up data from trials evaluating KEYTRUDA monotherapy for metastatic non-small cell lung cancer (NSCLC) will be presented [6]. Group 4: Clinical Research Program - Merck has the largest immuno-oncology clinical research program in the industry, with over 1,600 trials studying KEYTRUDA across various cancers and treatment settings [8].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Merck & Co., Inc. following a class action lawsuit alleging breaches of fiduciary duties by the board of directors during the class period from February 3, 2022, to February 3, 2025 [1][6]. Group 1: Class Action Lawsuit Details - The class action lawsuit claims that Merck made false or misleading statements regarding its revenue outlook and growth of Gardasil, while downplaying competition and drug approval risks [6]. - It is alleged that Merck's optimistic reports on growth and demand in China were not reflective of the actual situation, leading to a significant decline in Gardasil's market performance [6]. - Following a disclosure on July 30, 2024, regarding a significant drop in shipments, Merck's stock price fell nearly 10% [6]. - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion, with a more than 9% drop in stock price following this announcement [6]. Group 2: Legal Representation and Contact Information - Bragar Eagel & Squire, P.C. offers legal representation for individual and institutional investors in complex litigation [4]. - Investors who suffered losses in Merck are encouraged to contact the firm for more information regarding their rights and potential claims [3][7].

Company Performance - Merck's stock closed at $87.61, reflecting a -1.34% change from the previous day's closing price, underperforming the S&P 500 which lost 0.38% [1] - Over the past month, Merck's stock has increased by 5.6%, outperforming the Medical sector's gain of 2.72% and the S&P 500's gain of 4.06% [1] Upcoming Earnings - Merck is set to release its earnings report on October 30, 2025, with an expected EPS of $2.37, representing a 50.96% increase from the same quarter last year [2] - The consensus estimate for revenue is $17.19 billion, indicating a 3.18% increase from the same quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates predict earnings of $8.93 per share and revenue of $64.93 billion, reflecting changes of +16.73% and +1.19% respectively compared to the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Merck may indicate shifting business dynamics, with positive revisions suggesting optimism about the company's outlook [3][4] Zacks Rank and Valuation - Merck currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 9.94, which is below the industry average Forward P/E of 14.65 [5] - The company has a PEG ratio of 0.91, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.59 [6] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 21, placing it in the top 9% of over 250 industries [6][7]

Core Insights - Merck has initiated three phase IIb studies for its investigational TL1A inhibitor, tulisokibart (MK-7240), targeting three immune-mediated inflammatory diseases [1][2][7] - Tulisokibart is now being studied across six immune-mediated inflammatory diseases, expanding its clinical evaluation [3][7] - Merck's phase III pipeline has nearly tripled since 2021, enhancing its long-term growth potential with around 20 new vaccines and drugs expected to launch in the coming years [5][8][9] Study Details - The three new phase IIb studies focus on moderate-to-severe hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis [2][3] - Tulisokibart is also being evaluated in phase III studies for ulcerative colitis and Crohn's disease, along with another phase II study for systemic sclerosis-associated interstitial lung disease [3] Financial Performance - Year-to-date, Merck's shares have declined by 10.7%, contrasting with an 8.5% increase in the industry [4] - The recent acquisition of Verona Pharma for approximately $10 billion is expected to strengthen Merck's cardio-pulmonary pipeline [10] Pipeline and Product Development - Merck's pipeline includes promising candidates such as enlicitide decanoate/MK-0616 for hypercholesterolemia, bomedemstat/MK-3543 for essential thrombocythemia, and nemtabrutinib/MK-1026 for hematological malignancies [9] - The company is positioned to launch multiple new products, many of which have blockbuster potential [5][8]

Core Insights - Merck's shares have increased nearly 13% recently due to positive sentiment in the pharmaceutical sector following Pfizer's drug pricing deal with the Trump administration [1][4]. Drug Pricing and Market Impact - Pfizer will reduce prices of certain drugs to match those in comparable developed countries, supporting the Most Favored Nation pricing proposal [2]. - Pfizer will receive a three-year exemption from tariffs on pharmaceutical imports in exchange for increasing U.S. manufacturing investment, committing an additional $70 billion [3]. Merck's Strengths - Keytruda, Merck's leading drug, accounts for over 50% of its pharmaceutical sales and has driven steady revenue growth, with sales rising approximately 7% in the first half of 2025 [6][7]. - Merck is pursuing strategies to enhance Keytruda's long-term growth, including innovative combinations and a partnership with Moderna for a personalized mRNA cancer vaccine [8]. Pipeline and M&A Activity - Merck's phase III pipeline has nearly tripled since 2021, positioning the company to launch around 20 new vaccines and drugs in the coming years [10][11]. - The acquisition of Verona Pharma for approximately $10 billion will strengthen Merck's cardio-pulmonary pipeline [15]. Challenges and Sales Performance - Sales of the Gardasil vaccine have declined by 48% in the first half of 2025, primarily due to weak demand in China [16][17]. - Other vaccines and diabetes products are also experiencing declining sales, contributing to a challenging near-term outlook for Merck [18][32]. Patent Expiration and Competitive Pressure - Keytruda is set to lose patent exclusivity in 2028, raising concerns about Merck's reliance on this drug and its ability to grow its non-oncology business [19]. - Competitive pressure is expected to increase from new dual PD-1/VEGF inhibitors, which may challenge Keytruda's market position [20][21]. Valuation and Earnings Estimates - Merck's shares have underperformed the industry and the S&P 500, with a current price/earnings ratio of 9.41, lower than the industry average of 15.96 [22][25]. - Earnings estimates for 2025 have remained stable at $8.93 per share, while 2026 estimates have slightly declined [28]. Strategic Outlook - Despite challenges, Merck's new products are showing strong launches, and the approval of Keytruda Qlex may mitigate the impact of Keytruda's loss of exclusivity [30]. - A wait-and-see approach is recommended for investors, as the company navigates its current challenges and seeks sustainable growth [32].

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Completes Acquisition of Verona Pharma. ...